1. VonHoff DD, Rozencweig M, Soper WT, Helman LJ, Penta JS, Davis HL, Muggia FM. Whatever happened to NSC? Cancer Treat Rep 61: 759–768, 1977.
2. Smythe JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 5: 93–101, 1980.
3. Tobias JS, Tattersall MHN. Doing the best for the cancer patient. Lancet 1: 35–38, 1985.
4. Muggia FM, DeVita VT Jr. Comments on moral dilemmas in clinical cancer experimentation. Med Ped Oncol 4: 181, 1978.
5. Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM. Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: Protocols of the laboratory of toxicology. Cancer Chemother Rep 4: 1–30, 1973.